On April 23, 2026, CatalYm announced the dosing of the first patient in its Phase II/III VINCIT trial, a global study evaluating visugromab as a potential treatment for cancer-associated cachexia. The trial, formally known as the Visugromab IN Cachexia International Trial (VINCIT) and registered under NCT07112196 on ClinicalTrials.gov, marks a significant step in addressing a debilitating condition that affects up to 70% of patients with certain advanced cancers and contributes to 20-40% of cancer-related deaths.
Cachexia, characterized by involuntary weight loss, muscle wasting, and reduced treatment tolerance, remains without approved pharmacological therapies despite its high prevalence and impact on patient outcomes. Visugromab, CatalYm’s lead anti-GDF-15 antibody, targets growth differentiation factor 15 (GDF-15), a protein implicated in the metabolic dysregulation underlying cachexia. By neutralizing GDF-15, the drug aims to reverse weight loss and improve appetite and physical function in patients with advanced solid tumors.
The VINCIT trial is designed as a randomized, double-blind, placebo-controlled study enrolling approximately 518 participants with cachexia linked to non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and other solid tumors. In Part I of the trial, participants receive one of three dose levels of visugromab or placebo administered every four weeks for 12 weeks. The adaptive trial design allows for modifications based on interim data, supporting efficient evaluation of safety and efficacy.
Sujata Rao, MD, CatalYm’s Chief Medical Officer, emphasized the urgency of the trial, stating that cachexia remains one of the most under-addressed complications in oncology. She noted that promising weight gain data from earlier studies, combined with growing evidence of GDF-15’s central role in metabolic wasting, positioned the VINCIT trial as critical for establishing visugromab as a novel therapeutic option.
The first patient dosing took place at clinical sites participating in the global study, though specific locations were not disclosed in the announcement. CatalYm, headquartered in Munich, Germany, and San Francisco, USA, is advancing visugromab through its late-stage development program, with the VINCIT trial representing its fourth Phase 2b study of the antibody.
Elevated GDF-15 levels have been consistently observed in patients with cancer-associated cachexia, correlating with reduced food intake, increased energy expenditure, and muscle atrophy. Preclinical and early clinical data suggest that inhibiting GDF-15 signaling may mitigate these effects, offering a mechanistic approach to treating a condition that currently relies solely on nutritional support and symptom management.
As of the announcement, no pharmacological treatments for cachexia have received regulatory approval, underscoring the significant unmet need in oncology. The VINCIT trial’s focus on patient-reported outcomes, including changes in body weight, appetite, and physical activity, aligns with regulatory expectations for demonstrating meaningful benefit in debilitating conditions.
The trial’s global reach reflects the international burden of cancer-associated cachexia, with enrollment planned across multiple regions to ensure diverse representation. Participants will be monitored for adverse events throughout the study period, with safety oversight provided by independent ethics committees and regulatory authorities in each country.
CatalYm’s announcement did not disclose financial details of the trial or specify funding sources. However, the company’s progression into Phase II/III development suggests confidence in visugromab’s profile based on prior data. Earlier-phase studies have shown signals of weight stabilization and improved functional status in subsets of patients, though larger, controlled trials are required to confirm efficacy.
The VINCIT trial’s adaptive nature allows for potential adjustments to dosing regimens or sample size based on emerging data, a design increasingly used in oncology to accelerate development timelines while maintaining scientific rigor. Interim analyses will inform decisions about continuing to later phases or modifying trial parameters.
For patients and caregivers affected by cancer-associated cachexia, the initiation of the VINCIT trial offers a tangible sign of progress toward much-needed treatment options. While results are not expected for several months, the trial represents one of the most advanced efforts to date targeting the biological drivers of wasting in advanced cancer.
Official updates on the VINCIT trial, including enrollment progress and safety reports, are available through ClinicalTrials.gov using the identifier NCT07112196. CatalYm has committed to sharing key findings through scientific conferences and peer-reviewed publications as data mature.
As research into GDF-15 and metabolic regulation in cancer continues, therapies like visugromab may redefine supportive care in oncology by addressing not just tumor growth but also the systemic consequences of malignancy. The success of such approaches could improve quality of life, enhance treatment tolerance, and potentially extend survival for patients living with advanced cancer and cachexia.
World Today Journal will continue to monitor developments in the VINCIT trial and report on verified outcomes as they become available. Readers seeking reliable information on cancer cachexia and emerging therapies are encouraged to consult official trial registries and peer-reviewed sources.
Stay informed about the latest advances in medical innovation by following World Today Journal’s Health section. Share this article to help spread awareness of critical developments in supportive cancer care.